Cargando…

Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases

PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local co...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckstein, Jacob, Gogineni, Emile, Sidiqi, Baho, Lisser, Noah, Parashar, Bhupesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991541/
https://www.ncbi.nlm.nih.gov/pubmed/36896213
http://dx.doi.org/10.1016/j.adro.2023.101179
_version_ 1784902173511909376
author Eckstein, Jacob
Gogineni, Emile
Sidiqi, Baho
Lisser, Noah
Parashar, Bhupesh
author_facet Eckstein, Jacob
Gogineni, Emile
Sidiqi, Baho
Lisser, Noah
Parashar, Bhupesh
author_sort Eckstein, Jacob
collection PubMed
description PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local control (LC), overall survival (OS), and toxicity when treating spine metastases. METHODS AND MATERIALS: All patients at our institution who received spine SBRT from 2010 to 2019 with systemic therapy data available were reviewed retrospectively. The primary endpoint was LC. Secondary endpoints were toxicity (fracture and radiation myelitis) and OS. Kaplan-Meier analysis was used to determine whether IT sequencing (before versus after SBRT) and use of IT were associated with LC or OS. RESULTS: A total of 191 lesions in 128 patients met inclusion criteria with 50 (26%) lesions in 33 (26%) patients who received IT. Fourteen (11%) patients with 24 (13%) lesions received the first IT dose before SBRT, whereas 19 (15%) patients with 26 (14%) lesions received the first dose after SBRT. LC did not differ between lesions treated with IT before SBRT versus after SBRT (1 year 73% versus 81%, log rank = 0.275, P = .600). Fracture risk was not associated with IT timing (χ(2) = 0.137, P = .934) or receipt of IT (χ(2) = 0.508, P = .476), and no radiation myelitis events occurred. Median OS was 31.8 versus 6.6 months for the IT after SBRT versus IT before SBRT cohorts, respectively (log rank = 13.193, P < .001). On Cox univariate analysis and multivariate analysis, receipt of IT before SBRT and Karnofsky performance status <80 were associated with worse OS. IT treatment versus none was not associated with any difference in LC (log rank = 1.063, P = .303) or OS (log rank = 1.736, P = .188). CONCLUSIONS: Sequencing of IT and SBRT was not associated with any difference in LC or toxicity, but delivering IT after SBRT versus before SBRT was associated with improved OS.
format Online
Article
Text
id pubmed-9991541
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99915412023-03-08 Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases Eckstein, Jacob Gogineni, Emile Sidiqi, Baho Lisser, Noah Parashar, Bhupesh Adv Radiat Oncol Scientific Article PURPOSE: Stereotactic body radiation therapy (SBRT) is commonly used to treat spinal metastases in combination with immunotherapy (IT). The optimal sequencing of these modalities is unclear. This study aimed to investigate whether sequencing of IT and SBRT was associated with differences in local control (LC), overall survival (OS), and toxicity when treating spine metastases. METHODS AND MATERIALS: All patients at our institution who received spine SBRT from 2010 to 2019 with systemic therapy data available were reviewed retrospectively. The primary endpoint was LC. Secondary endpoints were toxicity (fracture and radiation myelitis) and OS. Kaplan-Meier analysis was used to determine whether IT sequencing (before versus after SBRT) and use of IT were associated with LC or OS. RESULTS: A total of 191 lesions in 128 patients met inclusion criteria with 50 (26%) lesions in 33 (26%) patients who received IT. Fourteen (11%) patients with 24 (13%) lesions received the first IT dose before SBRT, whereas 19 (15%) patients with 26 (14%) lesions received the first dose after SBRT. LC did not differ between lesions treated with IT before SBRT versus after SBRT (1 year 73% versus 81%, log rank = 0.275, P = .600). Fracture risk was not associated with IT timing (χ(2) = 0.137, P = .934) or receipt of IT (χ(2) = 0.508, P = .476), and no radiation myelitis events occurred. Median OS was 31.8 versus 6.6 months for the IT after SBRT versus IT before SBRT cohorts, respectively (log rank = 13.193, P < .001). On Cox univariate analysis and multivariate analysis, receipt of IT before SBRT and Karnofsky performance status <80 were associated with worse OS. IT treatment versus none was not associated with any difference in LC (log rank = 1.063, P = .303) or OS (log rank = 1.736, P = .188). CONCLUSIONS: Sequencing of IT and SBRT was not associated with any difference in LC or toxicity, but delivering IT after SBRT versus before SBRT was associated with improved OS. Elsevier 2023-01-16 /pmc/articles/PMC9991541/ /pubmed/36896213 http://dx.doi.org/10.1016/j.adro.2023.101179 Text en © 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Eckstein, Jacob
Gogineni, Emile
Sidiqi, Baho
Lisser, Noah
Parashar, Bhupesh
Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title_full Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title_fullStr Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title_full_unstemmed Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title_short Effect of Immunotherapy and Stereotactic Body Radiation Therapy Sequencing on Local Control and Survival in Patients With Spine Metastases
title_sort effect of immunotherapy and stereotactic body radiation therapy sequencing on local control and survival in patients with spine metastases
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991541/
https://www.ncbi.nlm.nih.gov/pubmed/36896213
http://dx.doi.org/10.1016/j.adro.2023.101179
work_keys_str_mv AT ecksteinjacob effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases
AT gogineniemile effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases
AT sidiqibaho effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases
AT lissernoah effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases
AT parasharbhupesh effectofimmunotherapyandstereotacticbodyradiationtherapysequencingonlocalcontrolandsurvivalinpatientswithspinemetastases